Buyback surprise: Livzon wants to take over 64.81% of Imexpharm!

Buyback surprise: Livzon wants to take over 64.81% of Imexpharm!

Livzon Pharmaceutical Group Inc., a leading company in the pharmaceutical sector, plans to buy back 64.81% shares of Imexpharm Corporation. The total value of this transaction is around VND5,730 billion. This is a significant step for Livzon and is intended to support the company's international expansion and sustainable development. The transaction was signed via a framework agreement on May 22, 2025 and is expected to be completed within nine months in order to obtain regulatory approval from competition authorities. The acquisition is subject to certain conditions, including compliance with permissible foreign ownership limits. This reports Vietnam.vn.

As part of the transaction, SK Investment Vina III is expected to receive more than VND4,210 billion, while Sunrise (Binh Minh Kim Investment Joint Stock Company) will receive VND862.5 billion and KBA Investment Joint Stock Company will receive nearly VND652 billion. These buybacks are carried out by Imexpharm's three main shareholders. The purchase price was determined based on bilateral negotiations and the average capitalization of Imexpharm in the last 30 trading sessions on the HOSE.

Details about Imexpharm Corporation

Imexpharm, founded in 1977, is characterized by a comprehensive portfolio that includes finished medicinal products, active ingredients as well as diagnostic reagents and devices. The company operates four factories with a total of 12 production lines that comply with EU GMP standards. Imexpharm has the largest antibiotic market share in Vietnam and currently holds 22.04% of the capital of Vietnam Pharmaceutical Corporation. The company aims to increase gross sales by an average of 15% per year from 2024 to 2030. .

SK Investment Vina III, Imexpharm's largest shareholder, has strategically invested in the company since 2020. At the end of 2020, SK held 24.02% of the shares. There are rumors of a possible divestment from SK, with market reporting from Bloomberg News indicating that the company plans to sell its 65 percent stake at the end of 2024. This possibility was discussed further at the annual general meeting on May 15, 2025.

Overall, Livzon's buyback of Imexpharm shows the active role that foreign investors play in the Vietnamese pharmaceutical market. Livzon, founded in 1985, has more than 9,000 employees and is engaged in the research, development, production and sales of pharmaceutical products. The acquisition will be financed from the internal resources of Livzon Pharmaceutical Group Inc.